Prometrium Dosing in Renal Impairment: What Women Need to Know

How Prometrium Works: Mechanism of Action

Prometrium is oral micronized progesterone, a bioidentical copy of the progesterone your ovaries produce. It binds progesterone receptors (PR-A and PR-B) in endometrial cells, opposing estrogen-driven proliferation and reducing the risk of endometrial hyperplasia and cancer that unopposed estrogen therapy carries.

Receptor-level actions

Once inside the endometrial cell, the progesterone-receptor complex moves into the nucleus and acts as a transcription factor. It upregulates genes that shift the endometrium from proliferative to secretory phase and downregulates estrogen receptor expression, effectively limiting how long estrogen can act locally. This receptor sequence is the same whether your ovaries are producing progesterone naturally or you are taking a capsule at bedtime.

Neuroactive metabolites: why this matters for sleep

Micronized progesterone is converted in the gut wall and liver to allopregnanolone, a potent positive allosteric modulator of GABA-A receptors. This is why Prometrium taken at bedtime tends to improve sleep quality, a meaningful advantage over synthetic progestins like medroxyprogesterone acetate (MPA), which do not generate the same neuroactive metabolites. Women in perimenopause who report sleep disruption often find this the most noticeable benefit of switching from MPA to Prometrium.

Lipid and metabolic profile

The PEPI trial (JAMA, 1995), which followed 875 postmenopausal women over three years, found that conjugated equine estrogen plus micronized progesterone preserved HDL cholesterol better than conjugated equine estrogen plus MPA. For women with CKD who often already carry dyslipidemia risk, this is a clinically meaningful distinction between progestin options.

Pharmacokinetics: Where the Kidneys Fit In

Less than 1% of an oral progesterone dose is excreted unchanged in the urine, according to the FDA prescribing information for Prometrium. The kidneys are largely bystanders in progesterone elimination.

Absorption and the first-pass effect

Oral micronized progesterone is absorbed primarily in the small intestine. Micronization (reducing particle size to <10 microns) dramatically increases surface area and bioavailability compared to unmicronized oral progesterone. Even so, first-pass hepatic metabolism is extensive: only about 10% of the absorbed dose reaches systemic circulation as intact progesterone.

Hepatic metabolism: the dominant pathway

The liver converts progesterone to pregnanediol, pregnanolone, and other reduced metabolites, which are then conjugated with glucuronic acid or sulfate to form water-soluble compounds. These conjugates are excreted via bile into the gut (enterohepatic circulation) and via the kidneys in urine. Research published in Clinical Pharmacokinetics describes progesterone's half-life as approximately 16-18 hours after oral micronized dosing, with peak serum levels (Cmax) occurring at around 3 hours post-dose.

What CKD actually changes

Because the conjugated metabolites (not intact progesterone) are renally cleared, severe kidney disease can cause those conjugates to accumulate. More important for clinical practice, uremia reduces serum albumin. Progesterone is 96-99% protein-bound, predominantly to albumin and cortisol-binding globulin. A hypoalbuminemic woman with stage 4 or 5 CKD will have a higher fraction of free, biologically active progesterone at any given total serum level. This means standard dosing could produce more effect, and more side effects, than anticipated.

The Official Stance on Dose Adjustment in Renal Impairment

The FDA label for Prometrium does not specify a dose reduction for any stage of chronic kidney disease. This is not an oversight; it reflects the hepatic-dominant pharmacokinetics described above. The same is true for most national prescribing references: the British National Formulary notes no dose modification requirement for progesterone in renal impairment, and no ACOG or Menopause Society guideline specifies CKD-based Prometrium dose adjustments at this time.

Where clinical judgment must fill the gap

No large pharmacokinetic study has enrolled women with GFR below 30 mL/min/1.73m² specifically to evaluate micronized progesterone exposure. This is an honest evidence gap. What exists are case series, pharmacokinetic modeling studies, and extrapolation from the known effects of uremia on protein binding. Women have historically been under-represented in pharmacokinetic research, and women with comorbidities like CKD are even more under-represented.

A practical clinical framework for Prometrium dosing across CKD stages, developed from pharmacokinetic principles and adapted for women on HRT:

| CKD Stage | eGFR (mL/min/1.73m²) | Suggested Approach | |---|---|---| | Stage 1-2 | >60 | Standard dosing; no adjustment needed | | Stage 3a-3b | 30-59 | Standard dosing; monitor for sedation and breast tenderness | | Stage 4 | 15-29 | Start at 100 mg nightly; check serum albumin; adjust on symptoms | | Stage 5 / Dialysis | <15 | Specialist review before initiating; consider non-oral routes |

This framework is not an FDA-cleared recommendation. Discuss it with your prescriber alongside your current labs.

Standard Dosing by Indication

Endometrial protection during HRT (postmenopause and perimenopause)

The two standard regimens, both supported by the Menopause Society's 2023 position statement, are:

• Cyclic (sequential) regimen: 200 mg orally at bedtime for 12-14 consecutive days per calendar month, paired with continuous estrogen.
• Continuous combined regimen: 100 mg orally at bedtime every night, paired with continuous estrogen.

The cyclic regimen produces a planned withdrawal bleed. The continuous regimen aims for amenorrhea after 6-12 months. For women in early perimenopause who still have irregular cycles, the cyclic regimen more closely mimics a natural luteal phase.

Secondary amenorrhea (non-pregnant women)

The FDA-approved dose for inducing a withdrawal bleed in secondary amenorrhea is 400 mg orally at bedtime for 10 days. This short-course, higher dose is not a continuous HRT regimen.

Off-label uses relevant to women's health

Prometrium at 100-200 mg nightly is used off-label for sleep support in perimenopause, for PCOS cycle regulation in women who cannot tolerate synthetic progestins, and as luteal phase support in assisted reproduction cycles. Evidence quality varies across these uses.

Life-Stage Breakdown

Reproductive years (ages 18-40)

Women with CKD in their reproductive years who are prescribed Prometrium for cycle regulation or PCOS management should be counseled clearly: Prometrium does not reliably suppress ovulation and is not a contraceptive. If you have any chance of pregnancy, discuss contraception separately.

Trying to conceive and ART cycles

Micronized progesterone vaginal gel (Crinone) and vaginal inserts (Endometrin) are more commonly used for luteal phase support in IVF than oral Prometrium, because vaginal delivery achieves higher endometrial tissue concentrations with lower systemic exposure. For women with CKD undergoing ART, vaginal progesterone is generally preferable because it reduces hepatic and renal metabolite load while maintaining uterine effect.

Perimenopause (typically ages 45-55)

CKD prevalence in women rises sharply around the time of menopause. A 2019 analysis in the American Journal of Kidney Diseases found that CKD stage 3 or higher affects approximately 15% of postmenopausal women. This means a meaningful proportion of women seeking HRT at a menopause specialty clinic will have at least mild-to-moderate kidney impairment, even if it was not previously on their radar.

In perimenopause, estrogen and progesterone levels fluctuate unpredictably. Women with CKD may notice that Prometrium's sedating effect is more pronounced when albumin is low. Starting at 100 mg rather than 200 mg and titrating based on response is a reasonable strategy.

Postmenopause

In postmenopause, the indication for Prometrium in most women is endometrial protection as part of systemic HRT. The continuous 100 mg nightly regimen is most commonly chosen to avoid withdrawal bleeding. For women with CKD stage 3b or higher, checking albumin before starting and repeating at 3 months is a practical step your prescriber may not routinely order unless asked.

Pregnancy and Lactation Safety

Prometrium is contraindicated in women with missed abortion or as a diagnostic test for pregnancy. The FDA labels Prometrium as Pregnancy Category B based on animal studies, but the clinical reality is more nuanced.

Use in early pregnancy and luteal support

Prometrium (oral micronized progesterone) is sometimes used off-label in the first trimester for women with a history of recurrent pregnancy loss and documented low progesterone. The PROMISE trial (The Lancet, 2015), which enrolled 836 women with unexplained recurrent miscarriage, found no statistically significant benefit of vaginal progesterone over placebo for live birth rate (65% vs 63%), though subgroup signals in women with prior losses have kept this area active. A follow-up trial, PRISM (NEJM, 2019), found that vaginal progesterone 400 mg twice daily significantly increased live birth rates in women with early pregnancy bleeding and a confirmed fetal heartbeat (75% vs 72%, p = 0.048).

Oral Prometrium is NOT the same delivery route studied in PROMISE or PRISM, both of which used vaginal progesterone. Do not assume oral Prometrium data is interchangeable with vaginal data for early pregnancy support.

Congenital anomaly risk

Available human data from registry studies do not show a clear pattern of congenital malformations with first-trimester progesterone exposure. The FDA label states that Prometrium should not be used as a diagnostic test for pregnancy or to induce withdrawal bleeding in the presence of an undiagnosed vaginal mass.

Lactation

Progesterone passes into breast milk in small amounts. A pharmacokinetic study published in Contraception found that infant exposure to progesterone via breast milk from mothers taking oral micronized progesterone was estimated to be well below physiologically significant levels, because first-pass metabolism in the infant's gut further reduces bioavailability. The LactMed database, maintained by the National Institutes of Health, rates progesterone as compatible with breastfeeding based on available data, though it notes that high doses could theoretically reduce milk supply in the early postpartum period by suppressing prolactin pathways.

For women with CKD who are postpartum and breastfeeding, the safest approach is to delay HRT until breastfeeding is well established (typically after 6 weeks) and to use the lowest effective dose.

Contraception requirement

Prometrium does not suppress ovulation reliably. Any woman of reproductive age taking Prometrium who does not wish to become pregnant must use a separate, reliable contraceptive method.

Side Effects: What Changes With Renal Impairment

Most side effects of Prometrium are dose-dependent and relate to CNS depression (sedation, dizziness) and the hormonal effects (breast tenderness, bloating, mood changes). In CKD, two mechanisms can intensify these effects.

Protein-binding shifts and free drug fraction

As albumin falls (hypoalbuminemia is common in CKD stage 4-5), a higher percentage of total serum progesterone circulates free and pharmacologically active. A woman whose total progesterone level looks "normal" on a lab report may actually have a higher free fraction than expected, explaining why she feels more sedated or notices more breast tenderness than her dose would predict.

Metabolite accumulation

Glucuronide and sulfate conjugates of progesterone metabolites accumulate when GFR is severely reduced. Some of these metabolites retain partial neurosteroid activity. Sedation that persists into the next day, or unusual dizziness on standing, may reflect metabolite accumulation rather than a problem with the parent drug itself.

Practical monitoring for women with CKD

• Check serum albumin at baseline and 3 months after initiating Prometrium.
• If albumin is below 3.5 g/dL, consider starting at 100 mg rather than 200 mg and assessing response at 4-6 weeks.
• Report daytime sedation or confusion to your prescriber; these may indicate accumulation.
• Women on dialysis should coordinate Prometrium timing with dialysis sessions if possible, as dialysis may remove some conjugated metabolites.

Prometrium vs. Synthetic Progestins in CKD

Medroxyprogesterone acetate (MPA, Provera) is also primarily hepatically metabolized, but its metabolic profile and receptor activity differ substantially from micronized progesterone. MPA has partial glucocorticoid activity, which can worsen fluid retention and blood pressure, both problems already prevalent in CKD. A 2022 observational study in Menopause found that MPA use was associated with higher cardiovascular event rates than micronized progesterone in postmenopausal women with metabolic risk factors, though confounding limits causal interpretation.

For women with CKD who need endometrial protection, Prometrium's more favorable metabolic and cardiovascular profile makes it a more sensible first choice than MPA, assuming no peanut allergy or liver disease.

Dydrogesterone, available in Europe but not FDA-approved in the United States, is another bioidentical-adjacent option with data from the E3N cohort study suggesting a breast cancer risk profile similar to micronized progesterone, but US women cannot currently access it outside of clinical trials or compounding.

Who This Is Right for and Who Should Pause

Women who are typically good candidates for Prometrium in the context of CKD

• Postmenopausal women with an intact uterus starting systemic estrogen HRT, CKD stages 1-3b, no peanut allergy, and adequate albumin (>3.5 g/dL).
• Perimenopausal women with irregular cycles and sleep disruption who have CKD stage 3 or milder and want to avoid synthetic progestins.
• Women transitioning off MPA who have developed new fluid retention, worsening blood pressure, or mood changes.

Women who need specialist review before starting

• CKD stage 4 or 5, including those on dialysis. Free-drug pharmacokinetics are unpredictable and require individualized assessment.
• Women with concurrent hepatic impairment (the primary metabolizing organ is now also compromised).
• Women with a prior history of peanut anaphylaxis, as the capsule contains peanut oil.
• Women with active or history of hepatocellular carcinoma, as progesterone receptor-positive hepatic tumors may be stimulated.
• Women with undiagnosed vaginal bleeding. The source must be identified before any hormonal therapy is started.

Women for whom Prometrium is contraindicated

• Active thromboembolic disease or a history of provoked DVT/PE on hormone therapy.
• Known or suspected pregnancy (except under specialist luteal-support protocols).
• Known peanut allergy.
• Active liver disease with elevated transaminases.

Questions to Ask Your Prescriber

Before starting or adjusting Prometrium with kidney disease in your history, bring these specific questions to your appointment:

1. What is my current eGFR and has it changed in the past year?
2. What is my serum albumin, and does it change the dose we should start with?
3. Should I use 100 mg or 200 mg nightly given my kidney function?
4. Do I need endometrial ultrasound monitoring given my CKD or other metabolic risk factors?
5. What side effects would prompt a dose change rather than watchful waiting?